13F Data
Security · CUSIP 88339KAA0

THERAVANCE BIOPHARMA INC

NOTE 3.250%11/0 · institutional ownership from 13F filings
13F holders
0
Shares held
0
Value held
$0
New / sold out
0 / 1
Added / reduced
0 / 0
net 0 shares

13F holders by quarter

Q4 2016: 1Q1 2017: 1Q2 2017: 1Q3 2017: 1Q4 2017: 1Q1 2018: 1Q2 2018: 1Q3 2018: 2Q4 2018: 2Q1 2019: 3Q2 2019: 2Q3 2019: 3Q4 2019: 3Q1 2020: 4Q2 2020: 4Q3 2020: 3Q4 2020: 2Q1 2021: 2Q2 2021: 3Q3 2021: 4Q4 2021: 4Q1 2022: 4Q2 2022: 1Q3 2022: 0
Q4 2016Q3 2022

Net shares bought by existing holders

Q4 2016: 1.0MQ1 2017: 0Q2 2017: 0Q3 2017: 0Q4 2017: -500.0KQ1 2018: 0Q2 2018: 0Q3 2018: 0Q4 2018: 0Q1 2019: 10.8MQ2 2019: -10.8MQ3 2019: 1.0MQ4 2019: 0Q1 2020: 3.3MQ2 2020: 0Q3 2020: -500.0KQ4 2020: -3.0MQ1 2021: 0Q2 2021: 5.0MQ3 2021: 9.5MQ4 2021: 500.0KQ1 2022: 150.0KQ2 2022: -16.5MQ3 2022: 0
Q4 2016Q3 2022

Top holders · Q3 2022

Nothing to show.

Biggest buyers

Nothing to show.

Biggest sellers

ManagerChangeShares changeChange %
CONCOURSE FINANCIAL GROUP SECURITIES, INC.Sold out0–